Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OXNARD, Calif., Dec. 20, 2016 -- CURE Pharmaceutical (OTC Pink:CURR), a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, announces today the completion of a going public transaction and the issuance of its new stock symbol - CURR.
“After nearly six years of intense R&D activities, CURE Pharmaceutical is pleased to finally become a publicly traded entity, and anticipates a series of exciting business development announcements in the months to come,” said Rob Davidson, CEO of CURE Pharmaceutical.
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the bucal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing, efficacy thereby widening the therapeutic index.
CURE Pharmaceutical is now traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]
